Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report) on October 5 and set a price target of €3.10. The company’s shares closed last Thursday at $3.00.
Telliez covers the Healthcare sector, focusing on stocks such as Genfit, Innate Pharma SA, and Adocia SA. According to TipRanks, Telliez has an average return of -4.7% and a 32.00% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Innate Pharma SA with a $3.27 average price target.
See the top stocks recommended by analysts >>
IPHYF market cap is currently $189.1M and has a P/E ratio of -2.98.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Innate Pharma SA (IPHYF) Company Description:
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
Read More on IPHYF:
